Stefan Reuter

Summary

Affiliation: Heinrich Heine University
Country: Germany

Publications

  1. doi Risk factors associated with older age in treatment-naive HIV-positive patients
    Stefan Reuter
    Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Dusseldorf, Germany
    Intervirology 55:147-53. 2012
  2. doi Prognostic factors for invasive aspergillosis in patients with haematological malignancies
    Stefan Reuter
    Division of Infectious Diseases and Clinical Immunology, Department of Internal Medicine III Haematology, Oncology, Rheumatology and Infectious Diseases, University Hospital of Ulm, Ulm
    Scand J Infect Dis 41:483-90. 2009
  3. doi Combined albendazole and amphotericin B against Echinococcus multilocularis in vitro
    Stefan Reuter
    Department of Internal Medicine, University Hospital of Ulm, Germany
    Acta Trop 115:270-4. 2010
  4. pmc Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
    S Reuter
    Clinic for Gastroenterology, Hepatology and Infectious, University Hospital, Dusseldorf, Germany
    Eur J Med Res 15:231-7. 2010
  5. doi Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients
    Stefan Reuter
    Clinic of Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Moorenstr 5, 40225 Duesseldorf, Germany
    Med Microbiol Immunol 200:39-49. 2011
  6. doi Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort
    Stefan Reuter
    Department of Gaastroenterology, Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Dusseldorf, Germany
    J Med Virol 83:187-95. 2011
  7. doi Palliative operation for the treatment of alveolar echinococcosis
    Klaus Buttenschoen
    General, Visceral and Transplantation Surgery, University of Ulm, Steinhoevelstrasse 9, 89075, Ulm, Germany
    Langenbecks Arch Surg 394:199-204. 2009
  8. ncbi Structured treatment interruption in patients with alveolar echinococcosis
    Stefan Reuter
    Section of Infectious Diseases and Clinical Immunology, Department of Medicine III, University Hospital of Ulm, Germany
    Hepatology 39:509-17. 2004
  9. pmc In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae
    Stefan Reuter
    Section of Infectious Diseases and Clinical Immunology, University Hospital of Ulm, Robert Koch Str 8, 89081 Ulm, Germany
    Antimicrob Agents Chemother 50:2966-70. 2006
  10. pmc Salvage treatment with amphotericin B in progressive human alveolar echinococcosis
    Stefan Reuter
    Section of Infectious Diseases and Clinical Immunology, Department of Medicine III, University Hospital of Ulm, Ulm, Germany
    Antimicrob Agents Chemother 47:3586-91. 2003

Collaborators

Detail Information

Publications19

  1. doi Risk factors associated with older age in treatment-naive HIV-positive patients
    Stefan Reuter
    Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Dusseldorf, Germany
    Intervirology 55:147-53. 2012
    ..In order to improve care for older HIV patients, we intended to gain insight into the specific features of transmission, epidemiology, immunology and antiretroviral treatment (ART) of this population...
  2. doi Prognostic factors for invasive aspergillosis in patients with haematological malignancies
    Stefan Reuter
    Division of Infectious Diseases and Clinical Immunology, Department of Internal Medicine III Haematology, Oncology, Rheumatology and Infectious Diseases, University Hospital of Ulm, Ulm
    Scand J Infect Dis 41:483-90. 2009
    ..In these settings, increased efforts of prevention, early diagnosis and aggressive treatment of IA are warranted in order to improve survival...
  3. doi Combined albendazole and amphotericin B against Echinococcus multilocularis in vitro
    Stefan Reuter
    Department of Internal Medicine, University Hospital of Ulm, Germany
    Acta Trop 115:270-4. 2010
    ..If our in vitro results hold true in vivo, sequential application of ABZ and AMB would be an effective means for long-term suppression of larval growth. Long-term tolerance of both drugs could be improved by a reduction of side effects...
  4. pmc Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
    S Reuter
    Clinic for Gastroenterology, Hepatology and Infectious, University Hospital, Dusseldorf, Germany
    Eur J Med Res 15:231-7. 2010
    ..Few data are available about the efficacy of maraviroc (MVC) during routine use. We characterized indications for MVC use and the efficacy of MVC in clinical practice...
  5. doi Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients
    Stefan Reuter
    Clinic of Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Moorenstr 5, 40225 Duesseldorf, Germany
    Med Microbiol Immunol 200:39-49. 2011
    ..OHBV infection constituted almost half of all HBV infections with detectable HBV DNA. Due to a lack of risk factors indicating OHBV infection, HBV diagnosis should not only include serological markers but also the detection of HBV DNA...
  6. doi Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort
    Stefan Reuter
    Department of Gaastroenterology, Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Dusseldorf, Germany
    J Med Virol 83:187-95. 2011
    ....
  7. doi Palliative operation for the treatment of alveolar echinococcosis
    Klaus Buttenschoen
    General, Visceral and Transplantation Surgery, University of Ulm, Steinhoevelstrasse 9, 89075, Ulm, Germany
    Langenbecks Arch Surg 394:199-204. 2009
    ..Even so, palliative resections are carried out, although cure cannot be achieved. As conservative treatment has improved, the role of palliative surgical procedures has to be redefined...
  8. ncbi Structured treatment interruption in patients with alveolar echinococcosis
    Stefan Reuter
    Section of Infectious Diseases and Clinical Immunology, Department of Medicine III, University Hospital of Ulm, Germany
    Hepatology 39:509-17. 2004
    ..If permanent discontinuation of benzimidazoles is attempted, the course of disease should be followed by PET...
  9. pmc In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae
    Stefan Reuter
    Section of Infectious Diseases and Clinical Immunology, University Hospital of Ulm, Robert Koch Str 8, 89081 Ulm, Germany
    Antimicrob Agents Chemother 50:2966-70. 2006
    ..The combination of NTZ plus ABZ was parasitocidal in vitro. Animal experiments are warranted for studies of dose, toxicity, and drug interactions...
  10. pmc Salvage treatment with amphotericin B in progressive human alveolar echinococcosis
    Stefan Reuter
    Section of Infectious Diseases and Clinical Immunology, Department of Medicine III, University Hospital of Ulm, Ulm, Germany
    Antimicrob Agents Chemother 47:3586-91. 2003
    ..Amphotericin B is not parasitocidal; therefore long-term treatment has to be anticipated...
  11. doi Assessment of disease activity in alveolar echinococcosis: a comparison of contrast enhanced ultrasound, three-phase helical CT and [(18)F] fluorodeoxyglucose positron emission tomography
    Alexander R Ehrhardt
    Department of Internal Medicine I, University Hospital Ulm, Robert Koch Str 8, 89081, Ulm, Germany
    Abdom Imaging 32:730-6. 2007
    ....
  12. doi Long-term experience on surgical treatment of alveolar echinococcosis
    Klaus Buttenschoen
    Department of General Surgery, University of Ulm, Steinhoevelstrasse 9, 89075, Ulm, Germany
    Langenbecks Arch Surg 394:689-98. 2009
    ..Alveolar echinococcosis (AE) is life-threatening and reports on surgical procedures and results are rare, but essential...
  13. ncbi Impeded Th1 CD4 memory T cell generation in chronic-persisting liver infection with Echinococcus multilocularis
    Burkhard J Manfras
    Division of Infectious Diseases and Clinical Immunology, Department of Internal Medicine, University of Ulm, Robert Koch Strasse 8, 89081 Ulm, Germany
    Int Immunol 16:43-50. 2004
    ..Whether the antigen-specific cellular hyporesponsiveness with impeded T(h)1 CD4(+) memory T cell generation is a cause or a result of the progressive metacestode activity remains to be determined...
  14. ncbi Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
    Christoph Wyen
    Department of Internal Medicine, University of Cologne, Cologne, Germany
    J Antimicrob Chemother 66:2092-8. 2011
    ....
  15. pmc Effect of amphotericin B on larval growth of Echinococcus multilocularis
    Stefan Reuter
    Section of Infectious Diseases, Department of Internal Medicine, University Hospital of Ulm, 89081 Ulm, Germany
    Antimicrob Agents Chemother 47:620-5. 2003
    ..It holds promise as an effective treatment option for otherwise fatal courses of disease...
  16. pmc Early clinical experiences with the new influenza A (H1N1/09)
    Ralf Winzer
    Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Universitatsklinikum Dusseldorf, Dusseldorf, Germany
    Dtsch Arztebl Int 106:770-6. 2009
    ..This means that the spread of the disease must be closely monitored...
  17. ncbi Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies
    Stefan Reuter
    Section of Infectious Diseases and Clinical Immunology, Department of Internal Medicine III, University Hospital of Ulm, Germany
    Clin Infect Dis 40:1087-93. 2005
    ..Bacterial antimicrobial resistance is likely to cause a progressive lack of efficacy of fluoroquinolones, but no convincing evidence from clinicoepidemiologic observations has proved this hypothesis...
  18. pmc Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine
    Jennifer Neubert
    Department of Pediatric Oncology, Center for Child and Adolescent Health, Medical Faculty, Heinrich Heine University Dusseldorf, Moorenstrasse 5, 40225 Dusseldorf, Germany
    BMC Pregnancy Childbirth 13:22. 2013
    ..The objective of this study was to investigate the effectiveness and safety of a risk adapted two week course of oral postnatal ZDV as part of a combined intervention to reduce MTCT...
  19. ncbi Analysis of transmission pathways of Pseudomonas aeruginosa between patients and tap water outlets
    Stefan Reuter
    Departments of Medical Microbiology and Hygiene, University Hospital of Ulm, Germany
    Crit Care Med 30:2222-8. 2002
    ..To study the association between infection and faucet contamination in a surgical intensive care unit (SICU)...